专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20180055823A1 Bendamustine Solution Formulations 审中-公开
公开(公告)号：US20180055823A1
公开(公告)日：2018-03-01
申请号：US15689895
申请日：2017-08-29
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： A61K31/4184 , A61K9/08 , A61K47/18
CPC分类号： A61K31/4184 , A61K9/0019 , A61K9/08 , A61K47/18 , A61P35/00 , A61P35/02
摘要： Liquid pharmaceutical formulation of Bendamustine that include bendamustine active pharmaceutical ingredient, N,N-Dimethylacetamide, and water in an amount of about 0.3% to 40%. The active pharmaceutical ingredient is Bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, preferably Bendamustine HCl monohydrate. The formulations contain 20-200 mg/mL Bendamustine. The formulations are stable upon long term storage at refrigerated conditions. They can be administered to treat neoplastic conditions without reconstituting prior to administration.

12. 发明授权

US09603930B2 Liquid bendamustine formulation 有权
公开(公告)号：US09603930B2
公开(公告)日：2017-03-28
申请号：US14959651
申请日：2015-12-04
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： A61K31/415 , A61K47/20 , A61K31/4184 , A61K9/08 , A61K47/18 , A61K47/10
CPC分类号： A61K47/20 , A61K9/0019 , A61K9/08 , A61K31/4184 , A61K47/10 , A61K47/18
摘要： The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of N,N-dimethylacetamide and glycerin, and an antioxidant. The bendamustine-containing compositions have less than about 2% of total impurities after two month storage at 25° C./60% RH. The pharmaceutical compositions may be used for treating neoplastic diseases.

13. 发明授权

US09475891B2 Process for the preparation of colesevelam hydrochloride 有权
标题翻译：盐酸利塞维兰的制备方法
公开(公告)号：US09475891B2
公开(公告)日：2016-10-25
申请号：US14490415
申请日：2014-09-18
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： C08F8/02 , C08F226/02 , A61K31/785
CPC分类号： C08F8/02 , C08F226/02
摘要： A novel process of manufacturing colesevelam hydrochloride including the steps of alkylating polyallylamine with n-decylbromide and 6-bromohexyl trimethyl ammonium bromide, followed by cross-linking the alkylated polyallylamine with epichlorohydrin in an aqueous medium, and adding a suitable chloride ion source to obtain colesevelam hydrochloride.
摘要翻译：一种制造盐酸利培氟铵的新方法，包括使用正癸基溴和6-溴己基三甲基溴化铵烷基化聚烯丙基胺，然后在水性介质中交联烷基化的聚烯丙基胺与表氯醇，并加入合适的氯离子源以获得大肠杆菌盐酸盐。

14. 发明授权

US07943585B2 Extended release antibiotic composition 有权
标题翻译：延长释放抗生素组成
公开(公告)号：US07943585B2
公开(公告)日：2011-05-17
申请号：US10743367
申请日：2003-12-22
申请人： Mahendra R. Patel , Bhaskarbhai C. Patel , Amol Singh Matharu
发明人： Mahendra R. Patel , Bhaskarbhai C. Patel , Amol Singh Matharu
IPC分类号： A01N43/04 , A61K31/70 , A61K9/22
CPC分类号： A61K9/2866 , A61K9/2054 , A61K9/209 , A61K31/7048
摘要： An extended-release antibiotic composition comprising at least one antibiotic, and greater than 50 weight percent, based on the total weight of the composition, of a polymer component, wherein said polymer component comprises at least one pharmaceutically acceptable hydrophilic polymer, and said polymer component has a viscosity of less than about 50 cps.
摘要翻译：基于组合物的总重量，包含至少一种抗生素和大于50重量％的延长释放抗生素组合物，其中所述聚合物组分包含至少一种药学上可接受的亲水性聚合物，并且所述聚合物组分具有小于约50cps的粘度。

15. 发明申请

US20100234566A1 Processes for Preparing a Polypeptide 审中-公开
标题翻译：制备多肽的方法
公开(公告)号：US20100234566A1
公开(公告)日：2010-09-16
申请号：US12727653
申请日：2010-03-19
申请人： Anup Kumar Ray , Hiren Kumar V. Patel , Johannes Ludescher , Mariappan Anbazhagan , Mahendra R. Patel , Ingolf Macher
发明人： Anup Kumar Ray , Hiren Kumar V. Patel , Johannes Ludescher , Mariappan Anbazhagan , Mahendra R. Patel , Ingolf Macher
IPC分类号： C07K1/08
CPC分类号： C08G69/10 , A61K38/00 , C07K14/001
摘要： The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate. The process comprises: (a) polymerizing a mixture of N-carboxyanhydride of L-tyrosine, N-carboxyanhydride of L-alanine, N-carboxyanhydride of a protected L-glutamate and N-carboxyanhydride of a protected L-lysine, in a polar aprotic solvent in the presence of an initiator, to form a protected polypeptide; (b) admixing an acid with the protected polypeptide formed in Step (a) and a solvent, to form a product; and (c) admixing a substance selected from the group consisting of an alkali or alkaline earth metal hydroxide, a carbonate, a hydrogencarbonate, and mixtures thereof, with the product formed in Step (b), and a solvent or a mixture of a solvent and water, to form a deprotected polypeptide or a pharmaceuticaly acceptable salt thereof.
摘要翻译：本发明涉及制备包含L-酪氨酸，L-丙氨酸，L-谷氨酸和L-赖氨酸的多肽或其药学上可接受的盐的改进方法。多肽或其药学上可接受的盐优选为醋酸格拉司他。该方法包括：（a）将L-酪氨酸的N-羧酸酐，L-丙氨酸的N-羧酸酐，受保护的L-谷氨酸的N-羧酸酐和受保护的L-赖氨酸的N-羧酸酐的极性在引发剂存在下的非质子溶剂，以形成受保护的多肽; （b）将酸与步骤（a）中形成的被保护的多肽和溶剂混合以形成产物; 和（c）将选自碱金属或碱土金属氢氧化物，碳酸盐，碳酸氢盐及其混合物的物质与步骤（b）中形成的产物和溶剂或溶剂的混合物和水，以形成去保护的多肽或其药学上可接受的盐。

16. 发明授权

US5587377A Terazosin crystalline polymorph and pharmaceutical compositions thereof 失效
标题翻译：特拉唑嗪结晶多晶型物及其药物组合物
公开(公告)号：US5587377A
公开(公告)日：1996-12-24
申请号：US547209
申请日：1995-10-24
申请人： Mahendra R. Patel , Kasireddy C. Reddy , Pankaj J. Dave
发明人： Mahendra R. Patel , Kasireddy C. Reddy , Pankaj J. Dave
IPC分类号： A61K31/505 , A61P9/00 , A61P9/12 , A61P13/02 , A61P15/00 , C07D405/12 , C07D239/84
CPC分类号： C07D405/12
摘要： The present invention relates to the discovery of novel polymorph form of an active pharmaceutical agent and the process for its preparation. More specifically, the present invention relates to the preparation of a novel polymorph form of terazosin hydrochloride, a well known anti-hypertensive agent.
摘要翻译：本发明涉及活性药剂的新型多晶型形式的发现及其制备方法。更具体地说，本发明涉及一种众所周知的抗高血压剂的新型多晶型形式的特拉唑嗪盐酸盐的制备。

17. 发明授权

US4304773A Novel bendroflumethiazide formulations and method 失效
标题翻译：新型弯甲氟噻嗪配方及方法
公开(公告)号：US4304773A
公开(公告)日：1981-12-08
申请号：US163128
申请日：1980-06-26
申请人： Thomas M. Wong , Mahendra R. Patel
发明人： Thomas M. Wong , Mahendra R. Patel
IPC分类号： A61K9/20 , A61K31/54 , A61K47/00
CPC分类号： A61K31/54 , A61K9/2004
摘要： New bendroflumethiazide formulations in solid form are provided which are characterized by excellent disintegration and dissolution capabilities even after long periods of storage. The new bendroflumethiazide formulations, for example, in the form of tablets, contain in addition to bendroflumethiazide, a combination of microcrystalline cellulose which serves as a diluent and aids in disintegration of the tablets, lactose which serves as a diluent, optionally starch (in the gelatinized form) which serves as a disintegrant, and one or more auxilliary disintegrants, such as sodium carboxymethyl starch, a tablet lubricant, such as magnesium stearate, and a colorant, if desired.A method for preparing the above formulations is also provided.
摘要翻译：提供固体形式的新的四氟嘧啶配方，其特征在于即使在长时间储存后也具有优异的崩解和溶解能力。新的四氟嘧磺隆配方，例如以片剂的形式，除了含有四氟嘧啶以外，还含有作为稀释剂的微晶纤维素的组合，有助于片剂的崩解，用作稀释剂的乳糖，任选的淀粉（在用作崩解剂的一种或多种辅助崩解剂，如羧甲基淀粉钠，片剂润滑剂如硬脂酸镁和着色剂。还提供了制备上述配方的方法。

18. 发明授权

US10905677B2 Bendamustine solution formulations 有权
公开(公告)号：US10905677B2
公开(公告)日：2021-02-02
申请号：US15689895
申请日：2017-08-29
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： A61K31/4184 , A61P35/02 , A61K9/00 , A61P35/00 , A61K9/08 , A61K47/18
摘要： Liquid pharmaceutical formulation of Bendamustine that include bendamustine active pharmaceutical ingredient, N,N-Dimethylacetamide, and water in an amount of about 0.3% to 40%. The active pharmaceutical ingredient is Bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, preferably Bendamustine HCl monohydrate. The formulations contain 20-200 mg/mL Bendamustine. The formulations are stable upon long term storage at refrigerated conditions. They can be administered to treat neoplastic conditions without reconstituting prior to administration.

19. 发明授权

US10869848B2 Carmustine pharmaceutical composition 有权
公开(公告)号：US10869848B2
公开(公告)日：2020-12-22
申请号：US16417013
申请日：2019-05-20
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： A01N37/00 , A61K31/215 , A01N37/12 , A01N37/44 , A61K31/24 , A01N25/00 , A61K31/175 , A61K31/00 , A61K9/19 , A61K47/10
CPC分类号： A61K31/175 , A61K9/19 , A61K31/00 , A61K47/10
摘要： The present invention provides pharmaceutical formulations of lyophilized carmustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized carmustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with carmustine, such as neoplastic diseases.

20. 发明申请

US20190269632A1 Carmustine Pharmaceutical Composition 审中-公开
公开(公告)号：US20190269632A1
公开(公告)日：2019-09-05
申请号：US16417013
申请日：2019-05-20
申请人： Mahendra R. Patel
发明人： Mahendra R. Patel
IPC分类号： A61K31/175 , A61K31/00 , A61K9/19
摘要： The present invention provides pharmaceutical formulations of lyophilized carmustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized carmustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with carmustine, such as neoplastic diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式